Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Patient-centric vs. source-centric RWD curation: Which is better?

Patient-centric vs. source-centric RWD curation: Which is better?

  • November 5, 2021
  • Posted in Marketplace
patient medical data marketplace

As a life science organization, you have several options when it comes to securing patient level real world data (RWD) to support your product launch or brand commercialization efforts. You can purchase directly from a data source, work with an aggregator, or use a digital patient medical data marketplace solution. 

The vast majority of options to purchase real world patient data via marketplace options are source-centric. 

You likely begin your data exploration by selecting the data sources you are most interested in (e.g. lab data, medical claims data, prescription claims data) and then drill down into some patient-specific criteria. 

Prognos Health’s patient medical data marketplace shifts the paradigm by putting patient-centric data buying centerstage. 

With this methodology, you start by defining the patient populations you wish to target by selecting key characteristics such as diagnosis, lab test results, procedure codes, therapy classes, and more in a patient medical data marketplace.

Then we present you with all of the data sources within the repository that contain clinically specific data fitting your the defined patient profile.  

Four advantages of a patient-centric approach:

  • It mirrors the patient-first approach most life science companies take when it comes to targeting and segmenting data to support a new product launch or commercialization effort 
  • Patient-centric RWD curation is more inclusive 
    1. Users are presented with all data sources that fit their desired patient profiles and there are options to quickly refine if necessary 
    2. This allows potentially valuable sources of patient information to be revealed that may have been excluded by limiting sources up front 
  • It helps eliminate double buying
    1. By pinpointing patient characteristics first, you eliminate purchasing the same patient data multiple times from different sources
  • The desired patient cohort is identified faster, accelerating purchasing and production timelines 

Realize the value of your RWD investments more quickly. 

Providing a patient-centric way to query and purchase patient-level RWD isn’t the only way Prognos Marketplace is different from the competition. The platform also provides:

  • Built-in AI and machine learning capabilities
  • Enhanced data standardization, linkability and analytics that deliver a single solution that can complement or replace your existing tools to support your end-to-end launch and commercialization efforts.

The time for change is now. Take a new approach to RWD curation and unlock unprecedented speed to health data value. Schedule a discovery call with one of our clinical experts today. 

« The Prognos/BHI partnership: 5 reasons their joint medical underwriting risk predictor is a straighter path to underwriting accuracy
Highlights from The Data Ecosystem in 2025 »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.